EGFR and non-small cell lung carcinoma: The tolerability and safety of volitinib as monotherapy or in combination with gefitinib in NSCLC patients with mutant or wild-type EGFR have been studied in several phase I trials (NCT01773018, NCT02374645).63 It was also assessed in combination with osimertinib for patients with resistant NSCLC harboring the T790M mutation in a phase II clinical study (NCT02143466).